tradingkey.logo

DarioHealth Corp

DRIO
查看詳細走勢圖
11.540USD
-1.300-10.12%
收盤 12/19, 16:00美東報價延遲15分鐘
78.10M總市值
虧損本益比TTM

DarioHealth Corp

11.540
-1.300-10.12%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-10.12%

5天

-2.94%

1月

-17.01%

6月

-16.38%

今年開始到現在

-26.60%

1年

-27.88%

查看詳細走勢圖

TradingKey DarioHealth Corp股票評分

單位: USD 更新時間: 2025-12-19

操作建議

DarioHealth Corp當前公司基本面數據相對非常健康,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名121/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價18.25。中期看,股價處於下降通道。近一個月,市場表現非常差,但技術面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

DarioHealth Corp評分

相關信息

行業排名
121 / 208
全市場排名
288 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 4 分析師
買入
評級
18.250
目標均價
+50.21%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

DarioHealth Corp亮點

亮點風險
DarioHealth Corp. is a global digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by data analytics, software, and personalized coaching. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management.
業績增長期
公司處於發展階段,最新年度總收入27.04M美元
估值合理
公司最新PE估值-1.04,處於3年歷史合理位
機構加倉
最新機構持股795.75K股,環比增加0.01%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉30.40K股

DarioHealth Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

DarioHealth Corp簡介

DarioHealth Corp. is a global digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by data analytics, software, and personalized coaching. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management.
公司代碼DRIO
公司DarioHealth Corp
CEORaphael (Erez)
網址https://shop.mydario.com/

常見問題

DarioHealth Corp(DRIO)的當前股價是多少?

DarioHealth Corp(DRIO)的當前股價是 11.540。

DarioHealth Corp 的股票代碼是什麼?

DarioHealth Corp的股票代碼是DRIO。

DarioHealth Corp股票的52週最高點是多少?

DarioHealth Corp股票的52週最高點是31.000。

DarioHealth Corp股票的52週最低點是多少?

DarioHealth Corp股票的52週最低點是5.935。

DarioHealth Corp的市值是多少?

DarioHealth Corp的市值是78.10M。

DarioHealth Corp的淨利潤是多少?

DarioHealth Corp的淨利潤為-40.98M。

現在DarioHealth Corp(DRIO)的股票是買入、持有還是賣出?

根據分析師評級,DarioHealth Corp(DRIO)的總體評級為買入,目標價格為18.250。

DarioHealth Corp(DRIO)股票的每股收益(EPS TTM)是多少

DarioHealth Corp(DRIO)股票的每股收益(EPS TTM)是-11.073。
KeyAI